# To Compare the Efficacy and Safety of HRS9531 and Placebo in Subjects With Overweight or Obese

> **NCT06396429** · PHASE3 · COMPLETED · sponsor: **Fujian Shengdi Pharmaceutical Co., Ltd.** · enrollment: 567 (actual)

## Conditions studied

- Overweight or Obesity

## Interventions

- **DRUG:** HRS9531 injection
- **DRUG:** HRS9531 injection
- **DRUG:** HRS9531 injection
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06396429
- **Lead sponsor:** Fujian Shengdi Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-05-13
- **Primary completion:** 2025-07-07
- **Final completion:** 2025-07-07
- **Target enrollment:** 567 (ACTUAL)
- **Last updated:** 2025-07-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06396429

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06396429, "To Compare the Efficacy and Safety of HRS9531 and Placebo in Subjects With Overweight or Obese". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT06396429. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*